A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants

Autor: Tameris, M., Hokey, D.A., Nduba, V., Sacarlal, J., Laher, F., Kiringa, G., Gondo, K., Lazarus, E.M., Gray, G.E., Nachman, S., Mahomed, H., Downing, K., Abel, B., Scriba, T.J., McClain, J.B., Pau, M.G., Hendriks, J., Dheenadhayalan, V., Ishmukhamedov, S., Luabeya, A.K.K., Geldenhuys, H., Shepherd, B., Blatner, G., Cardenas, V., Walker, R., Hanekom, W.A., Sadoff, J., Douoguih, M., Barker, L., Hatherill, M.

Publikováno v: In Vaccine 9 June 2015 33(25):2944-2954

FACTORS OF ACCEPTANCE LEVEL OF E-PAYMENT SYSTEM IN CUDDALORE DISTRICT

Autor: DHEENADHAYALAN, V., YOGALAKSHMI, A.

The banking industry heavily relies on technology. One industry that consistently looks for ways to use technology to improve customer services is banking. A growing interchange route for the delivery of banking services is e-payment. India, the seco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8f426ba428a0599751982fdda201112f

Historical evaluation of the in vivo adventitious virus test and its potential for replacement with next generation sequencing (NGS).

Autor: Barone PW; MIT Center for Biomedical Innovation, USA. Electronic address: pbarone@mit.edu., Keumurian FJ; MIT Center for Biomedical Innovation, USA., Neufeld C; MIT Center for Biomedical Innovation, USA., Koenigsberg A; MIT Center for Biomedical Innovation, USA., Kiss R; MIT Center for Biomedical Innovation, USA; UPSIDE Foods, USA., Leung J; MIT Center for Biomedical Innovation, USA., Wiebe M; MIT Center for Biomedical Innovation, USA., Ait-Belkacem R; Yposkesi, France., Azimpour Tabrizi C; Amgen, USA., Barbirato C; Merck KGaA, Germany., Beurdeley P; PathoQuest, France., Brussel A; PathoQuest, France., Cassart JP; GSK, UK., Cote C; PathoQuest, France., Deneyer N; GSK, UK., Dheenadhayalan V; AstraZeneca, UK., Diaz L; MilliporeSigma, USA., Geiselhoeringer A; Roche, Switzerland., Gilleece MM; Biogen, USA., Goldmann J; Merck, Sharpe and Dohme, USA., Hickman D; Eli Lilly, USA., Holden A; Sartorius, Germany., Keiner B; CSL Behring, USA., Kopp M; Amgen, USA., Kreil TR; Takeda, Austria., Lambert C; GSK, UK., Logvinoff C; Sanofi, France., Michaels B; Pfizer, USA., Modrof J; Takeda, Austria., Mullan B; Yposkesi, France., Mullberg J; BMS, USA., Murphy M; Eli Lilly, USA., O'Donnell S; Eli Lilly, USA., Peña J; Allogene, USA., Ruffing M; Boehringer Ingelheim, USA., Ruppach H; Charles River Laboratories, USA., Salehi N; Pfizer, USA., Shaid S; GSK, UK., Silva L; Genentech, USA., Snyder R; Thermo Fisher Scientific, USA., Spedito-Jovial M; PathoQuest, France., Vandeputte O; GSK, UK., Westrek B; Merck, Sharpe and Dohme, USA., Yang B; Genentech, USA., Yang P; Genentech, USA., Springs SL; MIT Center for Biomedical Innovation, USA. Electronic address: ssprings@mit.edu.

Publikováno v: Biologicals : journal of the International Association of Biological Standardization [Biologicals] 2023 Feb; Vol. 81, pp. 101661. Date of Electronic Publication: 2023 Jan 06.

Corrigendum: T-cell activation is an immune correlate of risk in BCG vaccinated infants

Autor: Fletcher, H, Snowden, M, Landry, B, Rida, W, Satti, I, Harris, S, Matsumiya, M, Tanner, R, O'Shea, M, Dheenadhayalan, V, Bogardus, L, Stockdale, L, Marsay, L, Chomka, A, Harrington-Kandt, R, Manjaly Thomas, Z, Naranbhai, V, Stylianou, E, Darboe, F, Penn-Nicholson, A, Nemes, E, Hatheril, M, Hussey, G, Mahomed, H, Tameris, M, McClain, J, Evans, T, Hanekom, W, Scriba, T, McShane, H

Publikováno v: Nature Communications

Vaccines to protect against tuberculosis (TB) are urgently needed. We performed a case–control analysis to identify immune correlates of TB disease risk in Bacille Calmette–Guerin (BCG) immunized infants from the MVA85A efficacy trial. Among 53 T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::ad2735adc67d1e3c3d9d10472b3358dc
http://ora.ox.ac.uk/objects/uuid:6ca5c29f-4608-4162-9ddd-05e037e2af2f

A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults

Autor: Sheehan, S, Harris, SA, Satti, I, Hokey, DA, Dheenadhayalan, V, Stockdale, L, Thomas, Z-R, Minhinnick, A, Wilkie, M, Vermaak, S, Meyer, J, O'Shea, MK, Pau, MG, Versteege, I, Douoguih, M, Hendriks, J, Sadoff, J, Landry, B, Moss, P, McShane, H

Publikováno v: PLoS ONE, Vol 10, Iss 11, p e0141687 (2015)
PLoS ONE

Background MVA85A and AERAS-402 are two clinically advanced viral vectored TB vaccine candidates expressing Mycobacterium tuberculosis antigens designed to boost BCG-induced immunity. Clinical trials with candidate malaria vaccines have demonstrated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::5a092f38d93b78bf9fec2ec6de5000c2
http://ora.ox.ac.uk/objects/uuid: